Dr. Tien Lee, Founder and CEO of Aardvark Therapeutics, joined Judy Shaw on #NYSEFloorTalk to talk about their innovative obesity drug, ARD-101. He shared how it stands out from other treatments, the encouraging data so far, and what their upcoming trials will focus on.
In the quest to tackle obesity, Aardvark Therapeutics is making waves with its innovative drug, ARD-101. This gut-restricted medication targets bitter taste receptors to effectively curb hunger, offering a fresh approach to weight management.
Recent Phase 2 studies have shown promising results, particularly in treating Prader-Willi syndrome and general obesity. Unlike traditional anti-appetite drugs, ARD-101 aims to minimize common side effects like nausea and weight regain, making it a potential game-changer in obesity treatment.
As Aardvark prepares for future trials, focusing on maintaining weight loss in patients transitioning from other treatments, the medical community eagerly awaits further data, expected by early 2026.
For a deeper dive into Aardvark Therapeutics and its groundbreaking work, check out the video below!
